Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
Want to Beat the Bear Market? Try These 2 Stocks
10:00am, Friday, 08'th Jul 2022 The Motley Fool
There's plenty of growth ahead for these companies.
7 Best Biotech Stocks to Buy in July 2022
07:35am, Friday, 08'th Jul 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared
Time To Board The ARKK
06:53am, Friday, 08'th Jul 2022 Seeking Alpha
Yesterday I made a call that the Market bottomed on 6/16. Barchart's Trend Spotter has moved from Sell to Hold on ARKK.
3 Top Healthcare Stocks to Buy for July
10:00am, Thursday, 07'th Jul 2022 The Motley Fool
The future looks bright for these players.
2 Reasons to Buy Vertex Pharmaceuticals Now
10:00am, Tuesday, 05'th Jul 2022 The Motley Fool
The stock gained momentum in the first half.
If You Invested $25,000 in Vertex Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today
03:00pm, Friday, 01'st Jul 2022 The Motley Fool
Has the stock provided investors with better gains than the S&P 500?
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:00am, Wednesday, 29'th Jun 2022 The Motley Fool
These players may change the world of medicine.
A Comprehensive Guide to Genomic ETFs
05:43pm, Tuesday, 28'th Jun 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.09%: What You Should Know
10:15pm, Monday, 27'th Jun 2022 Zacks Investment Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $66.90, marking a -0.09% move from the previous day.
Crispr Therapeutics: Use The Rally To Cut
05:21am, Sunday, 26'th Jun 2022 Seeking Alpha
CRISPR Therapeutics' price action remains close to its near-term resistance. Why do we believe CRSP stock proffers an opportunity to cut exposure? Find out.
Crispr Therapeutics: Use The Rally To Cut
01:21am, Sunday, 26'th Jun 2022
This is a dedicated price action analysis of CRISPR stock. We highlight why investors should consider cutting exposure as CRSP formed another bull trap in June, corroborating its bearish bias. Investo
Will CRISPR Stock Double in the Next Year?
10:23am, Friday, 24'th Jun 2022
On the long way down, in what appears to be a clear-cut recession, investors are looking at picking up names on the cheap for when the turnaround kicks in.
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
04:24pm, Thursday, 23'rd Jun 2022
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.
Should You Sell Biotech Stocks If There's a Recession?
02:37pm, Thursday, 23'rd Jun 2022 The Motley Fool
It's probably better to think about whether to buy more shares.
Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
12:04pm, Thursday, 23'rd Jun 2022
CRISPR Therapeutics shares traded as high as $200 18 months ago, but today the share price is $62, with a market cap valuation $4.75bn. I see that as a BUY opportunity. On Tuesday the company held an
